Список проголосовавших за комментарий "Bioverativ downgrade details — to Hold at Gabelli & Co on valuation (57.18)Gabelli & Co downgrades BIVV to Hold from Buy. Firm calls attention to the fact that shares are up 29% since they initiated coverage in Feb, and they no longer see a sufficient margin of safety to recommend purchase. Although potential upside is expected in a takeout scenario, firm does not see it as a NT catalyst. Firm recommends that investors Hold BIVV as a 4% discount to their 2018 PMV of $60 per share does not provide a sufficient margin of safety."